MCID: GNR004
MIFTS: 53

Generalized Anxiety Disorder

Categories: Mental diseases

Aliases & Classifications for Generalized Anxiety Disorder

MalaCards integrated aliases for Generalized Anxiety Disorder:

Name: Generalized Anxiety Disorder 12 72 36 51 14 69 59
Anxiety Generalized 51

Classifications:



External Ids:

Disease Ontology 12 DOID:14320
ICD10 32 F41.1
ICD9CM 34 300.02
NCIt 46 C92622
KEGG 36 H01662
UMLS 69 C0270549

Summaries for Generalized Anxiety Disorder

PubMed Health : 59
About generalized anxiety disorder: Everyone feels frightened or very scared every once in a while. In dangerous situations, for instance on the highway, fear can help to protect you. It puts the body in a state of readiness so that it can react to threats quickly. Worries and anxiety about the future, your job or family might also help to guard against danger. For example, by keeping you from making rash decisions that could lead to difficult situations.But if these sorts of fears become overwhelming, they can be very distressing. Some people end up constantly worrying about practically everything. If fears and anxiety overshadow everything else and don’t go away, the person may have developed generalized anxiety disorder (GAD). People with generalized anxiety disorder usually realize that their fears are exaggerated, but they aren’t able to control them. Although it’s difficult to get out of this state, there are treatments that can help.

MalaCards based summary : Generalized Anxiety Disorder, also known as anxiety generalized, is related to dysthymic disorder and bulimia nervosa 2. An important gene associated with Generalized Anxiety Disorder is HTR1A (5-Hydroxytryptamine Receptor 1A), and among its related pathways/superpathways are Circadian rythm related genes and cAMP signaling pathway. The drugs Alprazolam and Valproic Acid have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An anxiety disorder that is characterized by long-lasting anxiety that is not focused on any one object or situation.

Wikipedia : 72 Generalized anxiety disorder (GAD) is an anxiety disorder characterized by excessive, uncontrollable and... more...

Related Diseases for Generalized Anxiety Disorder

Diseases related to Generalized Anxiety Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 112)
# Related Disease Score Top Affiliating Genes
1 dysthymic disorder 30.2 HTR2A MAOA SLC6A4
2 bulimia nervosa 2 30.1 BDNF HTR2A SLC6A4
3 alcohol use disorder 30.1 DRD2 SLC6A4
4 social phobia 30.0 DRD2 HTR3A MAOA SLC6A4
5 alexithymia 29.8 DRD2 HTR1A SLC6A4
6 antisocial personality disorder 29.7 DRD2 MAOA SLC6A4
7 chronic fatigue syndrome 29.7 HTR1A MAOA SLC6A4
8 anxiety 29.6 BDNF CRHR1 HTR1A HTR2A HTR3A MAOA
9 eating disorder 29.6 BDNF DRD2 SLC6A4
10 neuroleptic malignant syndrome 29.5 DRD2 HTR1A
11 substance abuse 29.5 BDNF DRD2 MAOA SLC6A4
12 agoraphobia 29.3 HTR1A MAOA RGS2 SLC6A2 SLC6A4
13 oppositional defiant disorder 29.3 DRD2 MAOA SLC6A2 SLC6A4
14 substance dependence 29.2 BDNF DRD2 MAOA SLC6A4
15 post-traumatic stress disorder 29.2 BDNF DRD2 HTR2A MAOA SLC6A4
16 irritable bowel syndrome 29.1 CRHR1 HTR3A SLC6A4 TPH1
17 borderline personality disorder 28.6 BDNF HTR1A HTR2A MAOA SLC6A4 TPH1
18 personality disorder 28.5 BDNF DRD2 HTR1A HTR2A MAOA SLC6A4
19 obsessive-compulsive disorder 28.4 BDNF DRD2 HTR1A HTR2A HTR3A MAOA
20 attention deficit-hyperactivity disorder 28.0 BDNF DRD2 HTR1A HTR2A MAOA SLC6A2
21 migraine with or without aura 1 27.9 DRD2 HTR1A HTR2A HTR3A MAOA SLC6A4
22 bipolar disorder 27.6 BDNF DRD2 HTR1A HTR2A HTR3A MAOA
23 major depressive disorder 27.3 BDNF CRHR1 DRD2 HTR1A HTR2A HTR3A
24 mood disorder 27.3 BDNF CRHR1 DRD2 HTR1A HTR2A MAOA
25 schizophrenia 27.2 BDNF DRD2 HTR1A HTR2A HTR3A MAOA
26 panic disorder 27.0 BDNF CRHR1 HTR1A HTR2A HTR3A MAOA
27 alcohol dependence 26.8 BDNF CRHR1 DRD2 HTR1A HTR2A HTR3A
28 alzheimer disease 5 10.4 HTR2A SLC6A4
29 schizophrenia 5 10.4 HTR1A HTR2A
30 schizoid personality disorder 10.4 HTR1A HTR2A
31 hypoactive sexual desire disorder 10.4 HTR1A HTR2A
32 substance-induced psychosis 10.3 HTR1A HTR2A
33 atypical depressive disorder 10.3 MAOA SLC6A4
34 psychosexual disorder 10.3 HTR1A HTR2A SLC6A4
35 specific developmental disorder 10.2 BDNF SLC6A2 SLC6A4
36 kleptomania 10.2 HTR1A MAOA SLC6A4
37 rumination disorder 10.2 HTR1A HTR3A
38 alcohol-induced mental disorder 10.2 DRD2 SLC6A4
39 episodic pain syndrome, familial, 1 10.1
40 tardive dyskinesia 10.1 DRD2 HTR2A
41 premature ejaculation 10.1 HTR1A HTR3A SLC6A4
42 alcoholic psychosis 10.1 DRD2 HTR2A SLC6A4
43 bruxism 10.1 DRD2 HTR2A SLC6A4
44 motion sickness 10.1 HTR1A HTR3A
45 aging 10.1
46 dyspepsia 10.1 HTR1A HTR3A SLC6A4
47 torticollis 10.1 DRD2 TSPO
48 intermittent explosive disorder 10.1 HTR1A SLC6A4
49 temporal lobe epilepsy 10.1 BDNF HTR1A TSPO
50 bipolar i disorder 10.1 BDNF HTR1A HTR2A SLC6A4

Comorbidity relations with Generalized Anxiety Disorder via Phenotypic Disease Network (PDN): (show all 19)


Acute Cystitis Anxiety
Bronchitis Chronic Myocardial Ischemia
Dependent Personality Disorder Dysthymic Disorder
Esophagitis Histrionic Personality Disorder
Hypertension, Essential Hypochondriasis
Hypothyroidism Irritable Bowel Syndrome
Major Depressive Disorder Obsessive-Compulsive Disorder
Obsessive-Compulsive Personality Disorder Osteoporosis
Personality Disorder Schizophreniform Disorder
Somatization Disorder

Graphical network of the top 20 diseases related to Generalized Anxiety Disorder:



Diseases related to Generalized Anxiety Disorder

Symptoms & Phenotypes for Generalized Anxiety Disorder

GenomeRNAi Phenotypes related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.1 HTR3A SLC6A4 HTR1A
2 Decreased viability GR00381-A-3 9.1 HTR3A SLC6A4 HTR1A

MGI Mouse Phenotypes related to Generalized Anxiety Disorder:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.15 HTR1A TPH1 HTR2A TSPO HTR3A MAOA
2 cardiovascular system MP:0005385 9.97 HTR1A TPH1 TSPO MAOA RGS2 CRHR1
3 homeostasis/metabolism MP:0005376 9.85 DRD2 SLC6A4 HTR1A TPH1 TSPO HTR3A
4 endocrine/exocrine gland MP:0005379 9.8 DRD2 SLC6A4 HTR2A TSPO HTR3A BDNF
5 muscle MP:0005369 9.43 DRD2 SLC6A4 TPH1 HTR2A HTR3A RGS2
6 nervous system MP:0003631 9.28 SLC6A4 HTR1A HTR3A MAOA BDNF RGS2

Drugs & Therapeutics for Generalized Anxiety Disorder

PubMedHealth treatment related to Generalized Anxiety Disorder: 59

There are different ways to gradually get a handle on an anxiety disorder. It is unrealistic to expect a quick and simple “cure,” but you can find better ways to deal with stress and anxiety. Medication may also relieve some of the symptoms. There are different kinds of treatment approaches:Psychological treatments: These include approaches like cognitive behavioral therapy. This therapy can help you to learn how to control and then change your thoughts and fears.Relaxation techniques such as autogenic training and progressive muscle relaxation can help you to relax and handle stress better. These techniques are often part of psychological treatment.Medication: The most commonly used medications for anxiety disorders are antidepressants. Some people also use herbal sedatives such as valerian.Self-help: Self-help groups offer you the opportunity to share your thoughts, feelings and experiences with others who have the same condition. Some people also find it helpful to learn more about the disorder – be it from books, information leaflets or on the Internet.It is hard to get a handle on severe anxiety, but many people succeed over time. A therapist can help to reveal the underlying patterns of the worries and anxiety. With their guidance, it is possible to learn how to control harmful thoughts and behavior patterns so that they no longer dominate your life. It can take a lot of patience to find your way back to a life with less anxiety, but a noticeable improvement can often already be achieved after a few weeks.

Drugs for Generalized Anxiety Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 403)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alprazolam Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2 28981-97-7 2118
2
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
3
Glatiramer Acetate Approved, Investigational Phase 4,Phase 2,Phase 3 147245-92-9 3081884
4
Interferon beta-1b Approved Phase 4,Phase 2,Phase 3 145155-23-3
5
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
6 Racepinephrine Approved Phase 4 329-65-7
7
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59729-33-8 2771
8
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
9
Norepinephrine Approved Phase 4,Phase 3,Phase 2 51-41-2 439260
10
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
11
Tramadol Approved, Investigational Phase 4,Phase 2 27203-92-5 33741
12
Buspirone Approved, Investigational Phase 4,Phase 2 36505-84-7 2477
13
Sertraline Approved Phase 4,Phase 3,Phase 2 79617-96-2 68617
14
Lorazepam Approved Phase 4,Phase 2 846-49-1 3958
15
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3 148553-50-8 5486971
16
Eszopiclone Approved, Investigational Phase 4,Phase 2 138729-47-2 969472
17
Ziprasidone Approved Phase 4 146939-27-7 60854
18
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2 61869-08-7 43815
19
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
20
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
21
Tiagabine Approved, Investigational Phase 4,Phase 3 115103-54-3 60648
22
Zolpidem Approved Phase 4 82626-48-0 5732
23
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
24
Ethanol Approved Phase 4,Phase 2,Phase 3 64-17-5 702
25
Nicotine Approved Phase 4 54-11-5 89594 942
26
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
27
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
28
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
29
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 1 56-12-2 119
30
Menthol Approved Phase 4,Phase 3,Phase 2 2216-51-5 16666
31
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
32
Morphine Approved, Investigational Phase 4 57-27-2 5288826
33
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
34
Ropivacaine Approved Phase 4 84057-95-4 175805 71273
35
Chlordiazepoxide Approved, Illicit, Investigational Phase 4 58-25-3 2712
36
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
37
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
38
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
39
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
40
Meperidine Approved Phase 4 57-42-1 4058
41
Methadone Approved Phase 4 76-99-3 4095
42 Kava Approved, Investigational, Nutraceutical Phase 4,Phase 2 9000-38-8
43
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
44 Tandospirone Investigational Phase 4 87760-53-0
45 Anti-Anxiety Agents Phase 4,Phase 3,Phase 2
46 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
47 GABA Agents Phase 4,Phase 3,Phase 2,Phase 1
48 GABA Modulators Phase 4,Phase 3,Phase 2
49 Hypnotics and Sedatives Phase 4,Phase 3,Phase 2
50 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 746)

# Name Status NCT ID Phase Drugs
1 Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder Unknown status NCT00662259 Phase 4 Alprazolam (Xanax);Placebo
2 Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD Unknown status NCT00579280 Phase 4 quetiapine SR;divalproex sodium ER;placebo
3 Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI Unknown status NCT00176592 Phase 4 Betaseron;Copaxone
4 Sodium Bicarbonate in Cardiopulmonary Resuscitation Unknown status NCT01377337 Phase 4 sodium bicarbonate
5 Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly Completed NCT00701675 Phase 4 sertraline 50 mg daily;sertraline 100 mg daily;Placebo 50 or 100 mg
6 Escitalopram in Patients With Generalized Anxiety Disorder Completed NCT00902564 Phase 4 Escitalopram
7 A Study of Duloxetine in Elderly Generalized Anxiety Disorder Completed NCT01118780 Phase 4 Duloxetine;Placebo
8 An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder Completed NCT00961298 Phase 4 Duloxetine
9 Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety Disorder(GAD) Completed NCT00219349 Phase 4 escitalopram
10 Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder Completed NCT00624780 Phase 4 Pregabalin;Lorazepam;Pregabalin;Placebo
11 Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder Completed NCT00235508 Phase 4 Eszopiclone (Lunesta)
12 Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder Completed NCT00266409 Phase 4 Niravam;SSRI/SNRI
13 Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD) Completed NCT01172652 Phase 4 Ziprasidone;Placebo
14 Drug Therapy for Generalized Anxiety Disorder Among the Elderly Completed NCT00105586 Phase 4 Escitalopram
15 Microtuning a Bonafide Treatment for GAD Patients - A Randomized Controlled Trial. Completed NCT02039193 Phase 4
16 Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder Completed NCT00113295 Phase 4 Continued Paroxetine CR;Quetiapine;Placebo
17 A Pilot Study of Cranial Electrotherapy Stimulation[CES] for Generalized Anxiety Disorder Completed NCT00539357 Phase 4
18 Chamomile Therapy for Generalized Anxiety Completed NCT00645983 Phase 4
19 Effectiveness of Long-Term Versus Short-Term Treatment of Generalized Anxiety Disorder With Venlafaxine XR Completed NCT00183274 Phase 4 Venlafaxine XR;Placebo
20 Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects Completed NCT01033851 Phase 4
21 A Study of Risperidone Monotherapy in Bipolar Anxiety Completed NCT00167479 Phase 4 risperidone (Risperdal)
22 Aripiprazole for the Treatment of Refractory Anxiety Completed NCT00438386 Phase 4 Aripiprazole
23 Primary Care Intervention Strategy for Anxiety Disorders Completed NCT00347269 Phase 4 Psychotropic medication optimization
24 Lorazepam-Induced Toxicity in the Aged Completed NCT00044642 Phase 4 Lorazepam
25 Switching From an SSRI to Tiagabine(GABITRIL) in Order to Alleviate SSRI Induced Sexual Dysfunction Completed NCT00174850 Phase 4 Gaitril
26 A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients Completed NCT01201967 Phase 4
27 Ambien CR vs. Placebo For Treatment Of Insomnia Associated With Anxiety When Used Concomitantly With Escitalopram (Lexapro) Completed NCT00296790 Phase 4 zolpidem tartrate
28 Identifying Very Early Response to Seroquel Extended Release (XR) Augmentation for Major Depressive Disorder Completed NCT00892463 Phase 4 Quetiapine (Seroquel) XR
29 Acamprosate in Alcoholics With Comorbid Anxiety or Depression Completed NCT00330174 Phase 4 Acamprosate
30 Brain Markers of Anxiety Disorders and SSRI/CBT Treatment in Children and Adolescents Completed NCT01160588 Phase 4 Sertraline
31 Black Cohosh as Alternative Therapy for Treating Menopause-Related Anxiety Completed NCT00120458 Phase 4
32 A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and of Quetiapine Fumarate (Seroquel®) as Potentiation SSRI's, and SNRI's Treatment in Major Depression With Anxiety Completed NCT00229645 Phase 4 Quetiapine Fumarate (Seroquel®)
33 Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors Completed NCT00802919 Phase 4 Varenicline;Placebo for varenicline
34 Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
35 Minocycline as an Adjunct for the Treatment of Depressive Symptoms: Pilot Randomized Controlled Trial Completed NCT02263872 Phase 4 Minocycline
36 An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00385671 Phase 4 duloxetine hydrochloride;pregabalin;gabapentin
37 Effectiveness of Integrating Prenatal Care in Reducing HIV/STDs Among Young Pregnant Women Completed NCT00628771 Phase 4
38 A Study of the Effects of Lumacaftor/Ivacaftor on Exercise Tolerance in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation Completed NCT02875366 Phase 4 LUM/IVA;Placebo
39 Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity Completed NCT01863459 Phase 4 Lisdexamfetamine Dimesylate;placebo
40 Substudy on the Mechanistic Plausibility of the Clinical Benefits of Adaptive Servo-ventilation Completed NCT01164592 Phase 4
41 Duloxetine for Menopausal Depression Completed NCT01117857 Phase 4 Duloxetine
42 Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder Recruiting NCT01614041 Phase 4 Usual dose treatment of Tandospirone;Comparative high dose of tandospirone treatment
43 Efficacy of SNRI Treatment on Prefrontality in Patients With GAD and Other Comorbities Recruiting NCT01975480 Phase 4 Desvenlafaxine
44 Kava for the Treatment of Generalised Anxiety Disorder: A Double-Blind Randomised Placebo-Controlled Trial Recruiting NCT02219880 Phase 4
45 Psycho-biological Substrates of Therapeutic Benefit of Thermal Cure on Generalized Anxiety Disorders Recruiting NCT03277339 Phase 4 Paroxetine
46 Mindfulness-Based Cognitive Therapy for Depression and Anxiety Recruiting NCT02777905 Phase 4
47 Ketamine Infusion for Adolescent Depression and Anxiety Recruiting NCT02579928 Phase 4 Ketamine;Midazolam
48 Palliation of Dyspnea With Morphine in Patients With Interstitial Lung Disease Recruiting NCT02622022 Phase 4 Morphine hydrochloride
49 Probiotics for Prophylaxis of Postoperative Hirschsprungs Associated Enterocolitis Recruiting NCT02343562 Phase 4
50 Effect of Tramadol in Prevention of Postpartum Depression Recruiting NCT03309163 Phase 4 Tramadol;Hydromorphone;Ropivacaine (Epidural analgesia)

Search NIH Clinical Center for Generalized Anxiety Disorder

Genetic Tests for Generalized Anxiety Disorder

Anatomical Context for Generalized Anxiety Disorder

MalaCards organs/tissues related to Generalized Anxiety Disorder:

38
Brain, Heart, Testes, Spinal Cord, Lung, Prostate, T Cells

Publications for Generalized Anxiety Disorder

Articles related to Generalized Anxiety Disorder:

(show top 50) (show all 705)
# Title Authors Year
1
Psychiatrists' treatment preferences for generalized anxiety disorder. ( 29266492 )
2018
2
Difficulty concentrating in generalized anxiety disorder: An evaluation of incremental utility and relationship to worry. ( 29175616 )
2018
3
Mobile and traditional cognitive behavioral therapy programs for generalized anxiety disorder: A cost-effectiveness analysis. ( 29300754 )
2018
4
Client reflections on confirmation and disconfirmation of expectations in cognitive behavioral therapy for generalized anxiety disorder with and without motivational interviewing. ( 29357757 )
2018
5
The Diagnostic Value of Malondialdehyde, Superoxide Dismutase and Catalase Activity in Drug NaA^ve, First Episode, Non-Smoker Generalized Anxiety Disorder Patients. ( 29397670 )
2018
6
Impact of generalized anxiety disorder (GAD) on prehospital delay of acute myocardial infarction patients. Findings from the multicenter MEDEA study. ( 29383439 )
2018
7
Risk Factors, Clinical Presentations, and Functional Impairments for Generalized Anxiety Disorder in Military Personnel and the General Population in Canada. ( 29304289 )
2018
8
Abnormal spontaneous brain activity in patients with generalized anxiety disorder revealed by resting-state functional MRI. ( 29406370 )
2018
9
Intolerance of uncertainty in youth with obsessive-compulsive disorder and generalized anxiety disorder: A transdiagnostic construct with implications for phenomenology and treatment. ( 29426573 )
2018
10
Worry amplifies theory-of-mind reasoning for negatively valenced social stimuli in generalized anxiety disorder. ( 29254067 )
2018
11
Association Analysis of the Brain-Derived Neurotrophic Factor Gene Val66Met Polymorphism and Gender with Efficacy of Antidepressants in the Chinese Han Population with Generalized Anxiety Disorder. ( 29446659 )
2018
12
Using interpersonal process recall to compare patients' accounts of resistance in two psychotherapies for generalized anxiety disorder. ( 28910493 )
2017
13
Affective neuroimaging in generalized anxiety disorder: an integrated review. ( 28867941 )
2017
14
Predictors of remission from generalized anxiety disorder and major depressive disorder. ( 27863710 )
2017
15
In the grip of worry: cerebral blood flow changes during worry induction and reappraisal in late-life generalized anxiety disorder. ( 28949338 )
2017
16
Repetitive transcranial magnetic stimulation of the right dorsal lateral prefrontal cortex in the treatment of generalized anxiety disorder: A randomized, double-blind sham controlled clinical trial. ( 28533148 )
2017
17
Children's and parent's psychological profiles in selective mutism and generalized anxiety disorder: a clinical study. ( 29081005 )
2017
18
Brain structural changes in late-life generalized anxiety disorder. ( 28837828 )
2017
19
Executive function and other cognitive deficits are distal risk factors of generalized anxiety disorder 9 years later. ( 29224581 )
2017
20
Biological markers of generalized anxiety disorder. ( 28867939 )
2017
21
Emotion-focused therapy for generalized anxiety disorder: An exploratory study. ( 29251955 )
2017
22
Generalized Anxiety Disorder, worry and attention to threat: A systematic review. ( 28448826 )
2017
23
Resting-state functional connectivity in generalized anxiety disorder and social anxiety disorder: Evidence for a dimensional approach. ( 28478685 )
2017
24
Aberrant Functional Network Connectivity as a Biomarker of Generalized Anxiety Disorder. ( 29375339 )
2017
25
Psychometric analysis of the Generalized Anxiety Disorder scale (GAD-7) in primary care using modern item response theory. ( 28771530 )
2017
26
Early improvement predicts 8-week treatment outcome in patients with generalized anxiety disorder treated with escitalopram or venlafaxine. ( 29193711 )
2017
27
The Association between Generalized Anxiety Disorder, Subthreshold Anxiety Symptoms and Fear of Falling among Older Adults: Preliminary Results from a Pilot Study. ( 28452660 )
2017
28
Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: A meta-analysis. ( 28483071 )
2017
29
Integrating iCBT for generalized anxiety disorder into routine clinical care: Treatment effects across the adult lifespan. ( 28926805 )
2017
30
Genetics of generalized anxiety disorder and related traits. ( 28867940 )
2017
31
Spontaneous alterations of regional brain activity in patients with adult generalized anxiety disorder. ( 28790831 )
2017
32
Childhood adversity, adult stress, and the risk of major depression or generalized anxiety disorder in US soldiers: a test of the stress sensitization hypothesis. ( 28443533 )
2017
33
Error-Specific Cognitive Control Alterations in Generalized Anxiety Disorder. ( 28871288 )
2017
34
The influence of Generalized Anxiety Disorder on Executive Functions in children with ADHD. ( 28766128 )
2017
35
Reduction in Costs after Treating Comorbid Panic Disorder with Agoraphobia and Generalized Anxiety Disorder. ( 28418834 )
2017
36
Failure in Cognitive Suppression of Negative Affect in Adolescents with Generalized Anxiety Disorder. ( 28747683 )
2017
37
Association of Panic Disorder, Generalized Anxiety Disorder, and Benzodiazepine Treatment During Pregnancy With Risk of Adverse Birth Outcomes. ( 28903165 )
2017
38
Environmental transmission of generalized anxiety disorder from parents to children: worries, experiential avoidance, and intolerance of uncertainty. ( 28867938 )
2017
39
Association between Internet gaming disorder and generalized anxiety disorder. ( 29280398 )
2017
40
The association of generalized anxiety disorder and Somatic Symptoms with frequent attendance to health care services: A cross-sectional study from the Northern Finland Birth Cohort 1966. ( 28792287 )
2017
41
In the grip of worry: cerebral blood flow changes during worry induction and reappraisal in late-life generalized anxiety disorder. ( 28809854 )
2017
42
Combining Metacognitive Strategies with Traditional Cognitive Behavior Therapy in Generalized Anxiety Disorder: A Case Illustration. ( 28515551 )
2017
43
Prevalence of generalized anxiety disorder and major depression in health-care givers of disabled patients in Majmaah and Shaqra cities, Kingdom of Saudi Arabia. ( 28936144 )
2017
44
Pharmacokinetic evaluation of pregabalin for the treatment of generalized anxiety disorder. ( 28075650 )
2017
45
Emotion-focused perspective on generalized anxiety disorder: A qualitative analysis of clients' in-session presentations. ( 28893153 )
2017
46
Treatment of Generalized Anxiety Disorder with Gabapentin. ( 29387502 )
2017
47
Prefrontal and amygdala engagement during emotional reactivity and regulation in generalized anxiety disorder. ( 28501740 )
2017
48
Client Retrospective Accounts of Corrective Experiences in Motivational Interviewing Integrated With Cognitive Behavioral Therapy for Generalized Anxiety Disorder. ( 28072459 )
2017
49
Resting state functional connectivity in primary insomnia, generalized anxiety disorder and controls. ( 28500965 )
2017
50
Frequency-Specific Functional Connectivity Density as an Effective Biomarker for Adolescent Generalized Anxiety Disorder. ( 29259549 )
2017

Variations for Generalized Anxiety Disorder

Expression for Generalized Anxiety Disorder

Search GEO for disease gene expression data for Generalized Anxiety Disorder.

Pathways for Generalized Anxiety Disorder

Pathways related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
2
Show member pathways
11.94 BDNF DRD2 HTR1A
3 11.71 BDNF HTR1A HTR2A HTR3A MAOA SLC6A4
4 11.69 HTR1A HTR2A HTR3A MAOA SLC6A4 TPH1
5
Show member pathways
11.61 BDNF DRD2 MAOA
6
Show member pathways
11.56 DRD2 HTR1A HTR2A
7
Show member pathways
11.07 MAOA SLC6A2 SLC6A4
8
Show member pathways
10.85 MAOA SLC6A4
9
Show member pathways
10.75 MAOA TPH1
10 10.55 HTR1A HTR2A HTR3A MAOA SLC6A4 TPH1

GO Terms for Generalized Anxiety Disorder

Cellular components related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.43 CRHR1 DRD2 HTR1A HTR2A SLC6A2 SLC6A4
2 neuron projection GO:0043005 8.92 RGS2 SLC6A2 SLC6A4 TPH1

Biological processes related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 response to cocaine GO:0042220 9.58 DRD2 HTR3A
2 negative regulation of insulin secretion GO:0046676 9.57 DRD2 PSMD9
3 response to axon injury GO:0048678 9.56 DRD2 TSPO
4 regulation of dopamine secretion GO:0014059 9.55 DRD2 HTR2A
5 behavioral response to cocaine GO:0048148 9.54 DRD2 HTR2A
6 temperature homeostasis GO:0001659 9.52 DRD2 HTR2A
7 G-protein coupled serotonin receptor signaling pathway GO:0098664 9.51 HTR1A HTR2A
8 response to pain GO:0048265 9.49 SLC6A2 TSPO
9 vasoconstriction GO:0042310 9.48 HTR1A SLC6A4
10 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.46 DRD2 HTR2A
11 negative regulation of voltage-gated calcium channel activity GO:1901386 9.43 CRHR1 DRD2
12 behavior GO:0007610 9.4 HTR1A HTR2A
13 regulation of behavior GO:0050795 9.37 HTR1A HTR2A
14 monoamine transport GO:0015844 9.32 SLC6A2 SLC6A4
15 dopamine uptake involved in synaptic transmission GO:0051583 9.26 SLC6A2 SLC6A4
16 regulation of hormone secretion GO:0046883 9.16 HTR1A HTR2A
17 response to drug GO:0042493 9.02 DRD2 HTR2A SLC6A2 SLC6A4 TSPO
18 serotonin receptor signaling pathway GO:0007210 8.96 HTR1A HTR2A

Molecular functions related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 beta-tubulin binding GO:0048487 9.4 RGS2 SLC6A2
2 neurotransmitter receptor activity GO:0030594 9.37 HTR1A HTR2A
3 G-protein coupled serotonin receptor activity GO:0004993 9.32 HTR1A HTR2A
4 G-protein alpha-subunit binding GO:0001965 9.26 HTR2A RGS2
5 monoamine transmembrane transporter activity GO:0008504 9.16 SLC6A2 SLC6A4
6 dopamine:sodium symporter activity GO:0005330 8.96 SLC6A2 SLC6A4
7 serotonin binding GO:0051378 8.8 HTR1A HTR2A HTR3A

Sources for Generalized Anxiety Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....